REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Blood pressure drug joins fight against tough head & neck cancers
Disease control Recruiting nowThis early-stage study is testing the safety of a three-part treatment for head and neck cancer that has come back, spread a little, or hasn't responded to other treatments. It combines a common blood pressure medicine (losartan) with an immunotherapy drug (pembrolizumab) and ver…
Matched conditions: REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New pill targets advanced cancers in early safety trial
Disease control Recruiting nowThis is an early-stage study to find safe doses of a new oral drug called IACS-6274. It will be tested alone and in combination with other cancer drugs in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check for side e…
Matched conditions: REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for Tough-to-Treat head and neck cancers: can a drug duo outperform the standard?
Disease control Recruiting nowThis study is for people with advanced head and neck cancer that has returned or spread and has stopped responding to standard platinum-based chemotherapy. It aims to see if combining two immunotherapy drugs (pembrolizumab and cetuximab) helps patients live longer than using pemb…
Matched conditions: REFRACTORY HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 17, 2026 12:55 UTC